Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000947871-25-000162
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7267
2 JOINT FILING AGREEMENT ss4343261_ex99a.htm EX-99.A 6770
  Complete submission text file 0000947871-25-000162.txt   15809
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13G/A

Mailing Address 500 RIVER RIDGE DRIVE NORWOOD MA 02062
Business Address 500 RIVER RIDGE DRIVE NORWOOD MA 02062 617-963-0103
Corbus Pharmaceuticals Holdings, Inc. (Subject) CIK: 0001595097 (see all company filings)

EIN.: 464348039 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88716 | Film No.: 25629581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)